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Summary
 
A basic principle of immunology is that prior immunity results in complete protection against a
homologous agent. In this study, we show that memory T cells specific to unrelated viruses
may alter the host’s primary immune response to a second virus. Studies with a panel of heter-
ologous viruses, including lymphocytic choriomeningitis (LCMV), Pichinde (PV), vaccinia
(VV), and murine cytomegalo (MCMV) viruses showed that prior immunity with one of these
viruses in many cases enhanced clearance of a second unrelated virus early in infection. Such
protective immunity was common, but it depended on the virus sequence and was not neces-
sarily reciprocal. Cell transfer studies showed that both CD4 and CD8 T cell populations from
LCMV-immune mice were required to transfer protective immunity to naive hosts challenged
with PV or VV. In the case of LCMV-immune versus naive mice challenged with VV, there
was an enhanced early recruitment of memory phenotype interferon (IFN) 
 
g
 
–secreting CD4
 
1
 
and CD8
 
1
 
 cells into the peritoneal cavity and increased IFN-
 
g
 
 levels in this initial site of virus
replication. Studies with IFN-
 
g
 
 receptor knockout mice confirmed a role for IFN-
 
g
 
 in medi-
ating the protective effect by LCMV-immune T cell populations when mice were challenged
with VV but not PV. In some virus sequences memory cell populations, although clearing the
challenge virus more rapidly, elicited enhanced IFN-
 
g
 
–dependent immunopathogenesis in the
form of acute fatty necrosis. These results indicate that how a host responds to an infectious
agent is a function of its history of previous infections and their influence on the memory T cell
pool.
Key words: memory T cells • virus • heterologous viruses • protective immunity • immuno-
pathogenesis
 
I
 
t had been previously thought that memory T cells were
present at relatively low frequencies and were essentially
dormant, but recent studies have shown that, subsequent to
infections of mice with lymphocytic choriomeningitis virus
(LCMV),
 
1
 
 Pichinde virus (PV), or vaccinia virus (VV), vi-
rus-specific pCTL frequencies (pCTL/f) are maintained at
very high levels for the lifetime of the animal (1, 2). In the
well-characterized LCMV model a subpopulation of these
memory cells at any given time consists of cytolytically ac-
tive cycling cells (3–6) expressing IL-2 receptors (4, 7) and
high levels of adhesion molecules (8–10). When the im-
mune system is biased by a high frequency of precursors
specific for a given virus, some of these T cells originally
stimulated by one virus infection will cross-react with and
be stimulated by a second heterologous virus (11, 12). In-
fections of LCMV-immune mice with PV, VV, or MCMV
result in the activation of blast-size, LCMV-specific CTL
that are easily detectable in cytotoxicity assays without ad-
ditional in vitro stimulation (11, 12). Limiting dilution
analyses demonstrated that splenocytes from LCMV-
immune mice acutely infected with PV or VV contained
many T cell clones cross-reactive between LCMV and PV
or between LCMV and VV, whereas T cell clones from
nonimmune mice infected with these viruses did not show
this cross-reactivity to LCMV (12). The consequence of
this cross-reactive stimulation of memory T cells is that a
 
1
 
Abbreviations used in this paper:
 
 AFN, acute fat necrosis; FBS, fetal bovine
serum; IFN-
 
g
 
R KO, interferon 
 
g
 
 receptor knockout mice; LCMV, lym-
phocytic choriomeningitis virus; MCMV, murine cytomegalovirus;
MEF, mouse embryo fibroblast; MOI, multiplicity of infection; PEC,
peritoneal exudate cells; p/f, precursor frequency; PV, Pichinde virus;
VV, vaccinia virus.
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second virus infection will reactivate memory cells specific
for the first virus and help prime a T cell response to the
second unrelated virus. Given their high frequency (1, 2),
state of activation (3–6), and ease of further activation (13–
16), as well as their propensity for cross-reactivity with het-
erologous agents, we questioned whether memory cells
generated in response to one infectious agent would con-
tribute significantly to the progression of disease elicited by
a heterologous agent. In this study, we demonstrate that
prior immunity to one virus can significantly enhance
clearance of a second unrelated virus early in infection, be-
fore the development of the high affinity virus-specific T
cell response that occurs after stimulation of naive T cells.
In some selective virus sequences we demonstrate that prior
immunity to one virus not only clears the second unrelated
virus more rapidly but also results in enhanced immunopa-
thology due to an altered T cell response.
 
Materials and Methods
 
Mice.
 
C57BL/6 (H-2
 
b
 
) male mice and 129/SEV and IFN-
 
g
 
receptor knockout (IFN-
 
g
 
R KO; reference 17) mice of both
sexes were either purchased from The Jackson Laboratory (Bar Har-
bor, ME) or else bred in our facility and used at 2–12 mo of age.
 
Viruses.
 
LCMV, strain Armstrong, an RNA virus in the Old
World arenavirus family, was propagated in BHK21 baby hamster
kidney cells (18). The WR strain of VV, a DNA virus in the pox-
virus family (11), and the AN3739 strain of PV, an RNA virus in
the New World arenavirus family only distantly related to
LCMV, were propagated in L929 or BHK21 cells (11, 18, 19).
MCMV, strain Smith, a DNA virus in the herpesvirus family, was
obtained from salivary glands of infected BALB/c mice (20). For
acute virus infections, mice were injected intraperitoneally with
4 
 
3
 
 10
 
4
 
 PFU of LCMV, 2 
 
3
 
 10
 
4
 
, 4 
 
3
 
 10
 
5
 
, or 10
 
6
 
 PFU of VV,
10
 
6
 
 PFU of PV, or 10
 
4
 
 or 10
 
5
 
 PFU of MCMV.
 
Cell Lines.
 
KO (H-2
 
b
 
), an SV40-transformed kidney cell line
derived from a C57BL/6 mouse (21) and provided to us by Dr.
Satvir Tevethia (Pennsylvania State Medical Center, Hershey,
PA), was propagated in DMEM (GIBCO BRL, Gaithersburg,
MD) supplemented with 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME. L929 (H-2
 
k
 
), a con-
tinuous liver cell line derived from C3H mice, MC57G (H-2
 
b
 
), a
methylcholanthrene-induced fibroblast cell line from C57BL/6
mice, early passage mouse embryo fibroblast (MEF) cells from
C57BL/6 mice, and ATCC Vero cells were propagated in Eagle’s
MEM (GIBCO BRL). KO and MC57G cells were infected with
LCMV and PV at a multiplicity of infection (MOI) of 0.1–0.2
PFU/cell and incubated for 2 d at 37
 
8
 
C. All cell lines were sup-
plemented with 100 U/ml penicillin G, 100 
 
m
 
g/ml streptomycin
sulfate, 2 mM 
 
L
 
-glutamine, 10 mM Hepes, and 10% heat-inacti-
vated (56
 
8
 
C, 30 min) fetal bovine serum (FBS; Sigma Chemical
Co., St. Louis, MO).
 
Infection Protocol with Heterologous Viruses.
 
Mice were immu-
nized with a sublethal dose of one virus. After the rise and fall of
the acute T cell response and when the immune system had re-
turned to homeostasis (usually 6 wk or longer), the mouse was
challenged with the second virus. At 3–5 d after the second virus
infection, the spleen, fat pads, and/or liver were harvested, ho-
mogenized, and titrated for virus plaques, as previously described
(22). In mice infected with LCMV only the spleens were titrated,
as this strain of LCMV does not replicate in the liver or fat pads.
These viruses were used either in crude tissue culture superna-
 
tants or were purified over sucrose gradients and diluted in PBS.
Control naive mice were either left uninjected or injected with
tissue culture media or with culture media sedimented like virus
over a sucrose gradient, and there was no significant difference in
virus titer when any one of these methods was compared with
another. The control mice were always age matched to the ex-
perimental group and housed under exactly the same pathogen-
free conditions as the experimental group for the identical time
period. All mice used were healthy with no evidence of any un-
derlying disease.
 
Intracellular IFN-
 
g
 
 Staining.
 
Peritoneal cells from individual
mice were stained for intracellular IFN-
 
g
 
 based on a method pre-
viously described (23). Peritoneal cells at 2 
 
3
 
 10
 
6
 
 per tube were
stimulated with PMA (Sigma Chemical Co.) at 50 ng/ml and
ionomycin (Sigma Chemical Co.) at 500 ng/ml for 2 h at 37
 
8
 
C.
Then brefeldin A (Sigma Chemical Co.) was added at 10 
 
m
 
g/ml
for 2 h at 37
 
8
 
C enabling intracellular proteins to accumulate. Af-
ter the cells were washed with FACS
 
Ò
 
 buffer (PBS with 2% FBS
and 0.02% sodium azide) they were incubated with anti-Fc 
 
g
 
II
receptor antibody (PharMingen, San Diego, CA) as a blocking
antibody, for 10 min at 4
 
8
 
C. Then tricolor-conjugated anti–
mouse CD4 (clone CT-CD4; Caltag Laboratories, San Francisco,
CA) or CD8 (clone CT-CD8
 
a
 
; Caltag Laboratories) was added
for 30 min at 4
 
8
 
C. After two washes with FACS
 
Ò
 
 buffer the cells
were fixed with 200 
 
m
 
l of 2% paraformaldehyde for 20 min at
room temperature. They were then washed with FACS
 
Ò
 
 buffer
containing 0.5% saponin (Sigma Chemical Co.), a permeabilizing
agent, and then incubated in this buffer for another 10 min at
room temperature before adding PE-conjugated rat anti–mouse
anti-IFN-
 
g
 
 mAb (PharMingen) or control PE-conjugated rat
IgG
 
1
 
 isotype for 30 min at room temperature. They were then
washed two more times with FACS
 
Ò
 
 buffer with saponin and
then one time with FACS
 
Ò
 
 buffer before analysis on either a
FACS
 
Ò
 
 440 (Becton Dickinson & Co., Sparks, MD) or FACStar
 
Ò
 
Plus (Becton Dickinson & Co.). The total number of CD8
 
1
 
 and
CD4
 
1
 
 or the total number of CD8
 
1
 
 and CD4
 
1
 
 cells secreting
IFN-
 
g
 
 was determined by multiplying the percentage times the
total cell yield from each mouse. The total CD4
 
1
 
 percentages
may be an underestimate as these cells tend to downregulate the
CD4
 
1
 
 receptor on stimulation with PMA and ionomycin. That
was not a problem with the CD8
 
1
 
 cells.
 
LDA for Virus-specific CTL Precursors.
 
Adult 129/SEV and IFN-
 
g
 
receptor knockout mice (IFN-
 
g
 
R KO) mice were inoculated in-
traperitoneally with LCMV, and at the indicated times after in-
fection spleens were harvested. The LCMV-specific precursor
frequency (p/f) per CD8
 
1
 
 cell was quantified by LDAs of un-
sorted cells (12, 24). The percentage of CD8
 
1
 
 T cells was deter-
mined by fluorescent antibody staining and FACS
 
Ò
 
 analysis, as
previously described (12, 24). The limiting dilution assays used a
previously described method (12, 24). In brief, splenic lympho-
cytes from infected mice were harvested and titrated in U-bot-
tomed, 96-well plates with 24 replicates at each dilution. They
were stimulated with virus-infected PECs (3–4 
 
3
 
 10
 
4
 
/well) and
supplemented with irradiated splenic feeders (1–2 
 
3
 
 10
 
5
 
/well)
and growth factors provided by using a 16% culture supernatant
from IL-2–secreting, gibbon lymphoma tumor cell line MLA.144
(American Type Culture Collection, Rockville, MD; reference
25). After 4 d, the cultures were fed with 10
 
4
 
 irradiated, virus-
infected PEC.
On days 7–8 of culture, individual wells were split twofold and
assayed for cytolytic function on LCMV-infected or uninfected
syngeneic target cells (KO) using a modified 
 
51
 
Cr-release assay.
 
51
 
Cr-labeled targets (5 
 
3
 
 10
 
3
 
) were added to all wells, and after an 
1707
 
Selin et al.
 
8–10 h incubation at 37
 
8
 
C the supernatant was harvested. Posi-
tive wells were defined as those wells whose 
 
51
 
Cr-release ex-
ceeded the mean spontaneous release by 
 
.
 
3 standard deviations.
All wells that lysed uninfected syngeneic targets were eliminated
from the analysis. Frequencies were calculated using 
 
x
 
2
 
 analysis
according to Taswell (26) on a computer program kindly pro-
vided by Dr. Richard Miller (University of Michigan, Ann Ar-
bor, MI).
 
Cytotoxicity Assays.
 
Cell-mediated cytotoxicity was deter-
mined using a standard microcytotoxicity (CTL) assay (19). Vary-
ing numbers of effector leukocytes were plated in triplicate to
achieve the desired E/T ratio. 
 
51
 
Cr-labeled MC57G target cells (5 
 
3
 
10
 
3
 
), either uninfected or infected with virus, were added to all
wells, and after a 6 h incubation at 37
 
8
 
C the supernatant was har-
vested and counted. Data are expressed as percent specific 
 
51
 
Cr-
release 
 
5 
 
100 
 
3
 
 ([experimental cpm 
 
2
 
 spontaneous cpm]/[max-
imum release cpm 
 
2
 
 spontaneous release cpm]). Lytic units were
calculated using exponential fit method (27) provided by software
from Proteins International (Rochester Hills, MI). One lytic unit
was defined as the number of effector cells required to lyse 5% of
a population of 5 
 
3
 
 10
 
3
 
 targets in a 6 h CTL assay. A low per-
centage lysis was used for these calculations because some of the
samples examined had relatively low levels of killing, and we
wished to make quantitative comparisons within a wide range of
very low and high CTL activity. The spontaneous release for
each target used in these assays was 
 
,
 
20%.
 
Adoptive Cell Transfers.
 
C57BL/6 mice were injected intrave-
nously with one spleen equivalent (
 
z
 
5–10 
 
3
 
 10
 
7
 
 splenocytes)
of immunologically naive (nonimmune) leukocytes or LCMV-
immune (
 
.
 
6 wk after infection) leukocytes and challenged I.P.
with PV (10
 
6
 
 PFU) or VV (10
 
6
 
 PFU). In some experiments
LCMV-immune leukocytes were treated with anti-CD8 (rat
anti–mouse CD8 mAb, clone Lyt 2.43; reference 28) and comple-
ment (rabbit serum) to remove CD8
 
1
 
 T cells (29) or with anti-
CD4 (rat anti–mouse CD4 mAb, clone GK1.5) and complement
(guinea pig serum) to remove CD4
 
1
 
 T cells before transfer.
Spleens were harvested, homogenized, and plaque-assayed for vi-
rus titer at 3–4 d after infection. The effectiveness of the CD4
 
1
 
 or
CD8
 
1
 
 T cell depletion was monitored by staining with anti–
mouse CD4 (clone L3T4 RM4-4; PharMingen) or anti–mouse
CD8 (clone CD8a Ly-2(53-6.7); PharMingen; reference 3).
FACS
 
Ò
 
 analyses showed that the CD4
 
1
 
 or CD8
 
1
 
 T cell contam-
ination was 
 
,
 
2%.
 
Isolation of Fat Pad Lymphocytes.
 
The infiltrating leukocytes of
VV-challenged LCMV-immune mice were isolated from the fat
pads by mincing and digesting with collagenase B (200 mg/ml) in
MEM media plus 4% BSA for 1 h at 37
 
8
 
C, and then the lympho-
cytes were separated over Lympholite M (Cedarlane Labs.,
Hornby, Ontario, Canada) and analyzed.
 
Virus Titration.
 
The number of PFU was determined by
plaque assay using a 10% homogenate of tissue taken from indi-
vidual mice and 10-fold dilutions of this homogenate on the ap-
propriate cell line, ATCC vero cells for LCMV, PV, VV, and
MEF cells for MCMV. Results were expressed as the geometric
mean titers, i.e., the arithmetic averages of the logs for four or
five separate animals titrated for virus individually plus or minus
the SEM. Titers reported are log10 PFU per whole spleen, liver,
and both abdominal fat pads.
Scoring the Level of AFN. The level of acute fatty necrosis was
scored visually based on the severity of disease from level 0 to 7.
Levels 1 and 2 represent very mild to mild disease with a few
white necrotic spots on one or both lower abdominal fat pads;
levels 3 and 4 represent mildly moderate and moderate with
larger patches of necrosis of the lower abdominal fat pads and ex-
tension into the upper left quadrant fat pad around the spleen;
and levels 5 and 6 represent moderately severe to severe with very
extensive large patches of necrosis on the lower abdominal fat
pads and spotty fatty necrosis throughout omental fat pads as well
as the splenic fat pad; level 7 represents very severe disease with
such severe fatty necrosis that the organs are adherent to each
other.
Results
Prior Infection with a Heterologous Virus Induces Protective
Immunity to Unrelated Viruses. Table 1 shows viral titration
data from experiments in which mice immune to one virus
were challenged with any of a panel of heterologous vi-
ruses. Prior immunity to LCMV, PV or MCMV resulted
in significant 10–300-fold lower VV titers in three major
organs (spleen, fat pads, and liver) at 3–5 d after VV infec-
tion. Prior immunity to LCMV also resulted in a significant
5–13-fold lower PV titers 3–4 d after PV infection, while
immunity to MCMV provided a less dramatic but still sig-
nificant 2.5-fold decrease in PV titer of the fat pads. Immu-
nity to MCMV resulted in a significant sixfold lower virus
titer in the spleen of LCMV-infected mice; immunity to
PV lowered the splenic LCMV titer only 2.5-fold (the
Armstrong strain of LCMV does not replicate in the liver
or fat pad). Immunity to LCMV and PV resulted in a four-
and fivefold decrease, respectively, in liver titers in
MCMV-infected mice. In contrast, immunity to VV did
not significantly lower LCMV, PV, or MCMV titers. Prior
immunity to LCMV or PV significantly lowered VV titers
over a 2 log10 range of challenge virus dose (Table 2). This
protective effect of prior immunity lasted for long periods
of time after the original virus infection, as mice either 8 or
29 wk after LCMV infection demonstrated equal efficiency
at resisting PV challenge (Fig. 1 A) as did mice either 6 or
19 wk after MCMV infection challenged with VV (Fig. 1
B). These studies suggest that protective immunity be-
tween these four heterologous viruses is a common occur-
rence, but it is not universal to all virus combinations, as
there is a selective protective effect dependent on the se-
quence of virus infections.
These experiments were initially done with standard vi-
rus stocks derived from serum-containing tissue culture su-
pernatants but then were performed with purified virus
stocks to determine if cross-reactive responses to cellular
contaminants or FBS were influencing the results. Impuri-
ties such as FBS and cellular debris were removed by puri-
fication of the viruses over sucrose gradients, followed by
substantial 20–100-fold dilutions in PBS before inoculation
of mice. Use of purified and diluted viruses eliminated any
anamnestic response to FBS or cellular contaminants. With
elispot assays we did detect FBS-specific responses of CD41
cells to IFN-g and IL-4 when inoculations were done with
virus prepared in media containing 10% FBS (data not
shown), but no such responses were detected when puri-
fied or diluted virus preparations were used. For the pro-
tective immunity experiments, however, the conventional1708 Protective Heterologous Antiviral Immunity
virus stocks and purified viruses produced similar results, so
all the results were pooled for the analyses in Table 1. It
should be further noted that the virus stocks were grown in
different cell lines; LCMV was grown in BHK cells, PV
was grown in BHK or L929 cells, and VV was grown in
NCTC929 cells or L929 cells (11 and 12). MCMV was de-
rived directly from mouse salivary glands (11). Also, serum
from LCMV-, PV-, and VV-immune mice infected with
the unpurified virus stocks did not demonstrate any anti-
body production against L929 or BHK cell surface mole-
cules by FACSÒ analysis (data not shown). All this informa-
tion makes it highly unlikely that a cellular contaminant
influenced the protective immunity.
T Cell Dependence of Heterologous Immunity. Adoptive cell
transfer of LCMV-immune splenocytes into naive mice
resulted in five- to eightfold more rapid virus clearance in
the spleen and fat pads, on VV or PV challenge than in
mice adoptively reconstituted with naive splenocytes (Fig.
2). These results supported the concept that the protective
heterologous immunity against acute VV and PV infections
was dependent on immune lymphocytes. Depletion of ei-
ther CD81 (Fig. 2, A and C) or CD41 (Fig. 2, B and D) T
cells before the cell transfer resulted in a loss of this protec-
tive effect, suggesting that both memory T cell types were
required. Studies were done to examine whether CD41
memory T cells were required for reactivation of the
Table 1. Heterologous Immunity Between Viruses
Mean (6 SEM) Log10 Change in Challenge Virus Titer* in the Immune versus the Naive Spleen‡
Immunizing virus Challenge virus (range of mean log10 of naive mice challenged with virus)§
LCMV (5.5–6.0) PV (3.7–4.0) MCMV (3.4) VV (3.2–4.1)
LCMV ND 21.1 6 0.2 (3)i 20.4 (1) 21.5 6 0.4 (4)i
PV 20.4 6 0.1 (3) ND UND 21.8 6 0.4 (4)i
MCMV 20.8 6 0.1 (3)i 20.5 6 0 (2) ND 21.5 6 0.4 (3)i
VV 20.3 6 0.2 (3) 20.1 6 0.2 (3) UND ND
Mean (6 SEM) Log10 Change in Challenge Virus Titer* in the Immune versus the Naive Fat Pad‡
Immunizing virus Challenge virus
LCMV PV (4.3–5.1) MCMV (3.7) VV (4.4–5.8)
LCMV ND 20.7 6 0.1 (3)i 20.2 (1) 21.8 6 0.3 (5)i
PV ND ND UND 22.4 6 0.4 (4)i
MCMV ND 20.4 6 0.06 (3)i ND 22.5 6 0.3 (3)i
VV ND 20.2 6 0.1 (4) UND ND
Mean (6 SEM) Log10 Change in Challenge Virus Titer in the Immune versus the Naive Liver‡
Immunizing virus Challenge virus
LCMV PV (2.7–3.6) MCMV (3.9–4.7) VV (3.6–4.6)
LCMV ND 20.7 6 0.06 (3)i 20.6 6 0.1 (4)¶ 21.0 6 0.3 (5)i
PV ND ND 20.7 6 0.3 (2) 21.6 6 0.05 (2)i
MCMV ND 20.3 6 0 (2) ND 21.5 6 0.1 (3)i
VV ND 20.1 6 0.1 (3) 0.0 (1) ND
Prior immunity to one virus can lower viral titer after infection with a heterologous virus. UND, the titer of MCMV was undetectable in both naive
and immunized mice. MCMV titer was detectable in the spleen and fat pad of mice in only one experiment. As these experiments were done over a
number of years a new stock of virus was used for the later experiments, and this virus stock cleared very rapidly from the spleens and fat pads of
older mice even when using the maximal dose of virus which could be given without being lethal in this time frame. Therefore we only have liver
titer data available with these later experiments.
*VV, PV, and LCMV were titrated on ATCC vero cell monolayers using 3-, 4-, and 5-d plaque assays, respectively. MCMV was titrated on mouse
embryo fibroblasts using a 5-d plaque assay.
‡Data are presented as average of mean reduction of titers in multiple experiments 6 SEM. The number in parentheses represents the number of ex-
periments that were done to derive the mean log10 decrease in virus titer. There were four to five mice per treatment group. The infection of mice
was done as described in Materials and Methods.
§The number in parentheses after each challenging virus represents the range of mean log10 of naive mice challenged with the virus indicated.
iStatistically significant difference between naive and immunized groups of mice (two-way Analysis of Variance with replication, P , 0.0001).
¶Statistically significant difference between naive and immunized groups of mice (two-way Analysis of Variance, P 5 0.02).1709 Selin et al.
LCMV-specific memory CTL in mice challenged acutely
with PV. Depletion of CD41 T cells in vivo by inoculation
with anti-CD4 mAb did not have a significant effect on
PV-specific CTL induction in PV-infected control or
LCMV-immune mice. In LCMV-immune mice chal-
lenged with PV, the reactivated LCMV-specific bulk CTL
activity (3) in the control group was 6.3 6 1.4 lytic units
(LU; calculated as 5% lysis of 5 3 103 targets) per 106 sple-
nocytes (n 5 18) in bulk assays, but in the CD41 T cell–
depleted mice it was dramatically lower, at ,1.2 6 0.1 LU
per 106 splenocytes (n 5 6). All of these mice were de-
pleted of NK cells with mAb to NK1.1 in order to reduce
background cytotoxicity to better resolve the virus-specific
killing (12). These results collectively suggest that CD41 T
cells were required for the heterologous activation of
CD81 CTL and that both CD41 and CD81 memory T
cells were required for protective immunity.
Requirement of IFN-g for Heterologous Immunity to VV.
A property of memory T cells is their ability to produce
much higher levels of cytokines than do naive cells after
stimulation (14). Therefore, we hypothesized that a heter-
ologous virus that stimulated memory T cells would elicit a
potent IFN-g response, a cytokine to which VV is known
to be extremely sensitive (17, 30). Analysis by ELISA assay
of IFN-g concentrations (Fig. 3 I) in the peritoneal fluid of
LCMV-immune mice at day 3 after VV infection (16,115 6
4,262 pg/ml, n 5 12) revealed .1,074-fold higher titers of
IFN-g than in uninfected naive mice (,15 6 0 pg/ml, n 5
8) or LCMV-immune mice (,15 6 0 pg/ml, n 5 8) and
5.4-fold (2,979 6 1,039 pg/ml; n 5 12; Student’s t test, P 5
0.007) more than control mice challenged with VV.
LCMV-immune mice challenged with PV did not show
this enhanced production of IFN-g (Fig. 3 II) nor did VV-
immune mice challenged with LCMV (data not shown).
We then examined the peritoneal cavity more closely, as
this is the site of initial VV replication where the most sig-
nificant impact on early virus replication could occur.
FACSÒ staining of PECs resolved a significant 8- and 2.7-
fold enhanced recruitment of CD81 and CD41 T cells, re-
spectively, in the LCMV-immune versus naive mice 3 d af-
Table 2. Prior Immunity to LCMV or PV Can Lower VV Titer Independently of the Challenge Dose
Virus infections*
Immune
VV Titer (mean log10 PFU/ml 6 SEM)‡
Acute VV infection
virus dose Spleen Fat pads Liver
PFU
NAIVE 2 3 104 ,1.4 6 0.2 3.4 6 0.7 2.9 6 0.2
LCMV 2 3 104 ,1.1 6 0.05 ,2.1 6 0.1§ ,2.3 6 0.2§
PV 2 3 104 ,1.0 6 0 ,2.6 6 0.4§ ,2.2 6 0.1§
NAIVE 4 3 105 4.0 6 0.3 4.8 6 0.3 4.9 6 0.3
PV 4 3 105 1.7 6 0.3§ 2.5 6 0.5§ 2.1 6 0.2§
NAIVE 1 3 106 3.5 6 0.2 5.8 6 0.3 3.6 6 0.3
LCMV 1 3 106 ,1.0 6 0§ ,2.9 6 0.05§ ,2.0 6 0.4§
PV 1 3 106 ,1.4 6 0.3§ ,2.4 6 0.5§ ,2.0 6 0§
*The infection of mice was done as described in Materials and Methods.
‡VV was titrated on ATCC vero cell monolayers using a 3-d plaque assay.
§Statistically significant difference between naive and immunized mice (Student’s t test, P , 0.05).
Figure 1. Prior immunity to one virus can lower virus titer to second
virus independently of the time after infection with the first virus. The in-
fection of mice was done as described in Materials and Methods. (A) Ti-
ters of PV in spleen, fat pad, and liver of age matched naive mice (black
bars) and LCMV-immune mice (cross-hatched bars) challenged with PV ei-
ther 8 or 29 wk after the initial LCMV infection. (B) Titers of VV in
spleen, fat pad, and liver of age-matched naive mice (black bars) and
MCMV-immune mice (cross-hatched bars) challenged with VV 6 or 19 wk
after the initial MCMV infection. *Represents statistically significant dif-
ference between naive and immunized mice (Student’s t test, P , 0.05).1710 Protective Heterologous Antiviral Immunity
ter challenged with VV (Fig. 4, A and B). Furthermore, the
peritoneal T cells in the LCMV-immune mice 3 d after
challenge with VV were predominantly of the memory
phenotype, CD44hi. Basing our cutoff value for CD44hi
(FITC-conjugated anti-CD44; PharMingen) at a mean flu-
orescence of 12.6 units as determined on naive splenocytes,
it was found that 92 6 5% (n 5 3) of the peritoneal CD81
cells and 75 6 19% (n 5 3) of the peritoneal CD41 cells
were CD44hi memory phenotype. The CD81 cells had a
mean fluorescence of 182 6 40 and the CD41 cells had a
mean fluorescence of 177 6 58. These cells were examined
for expression of intracellular IFN-g after treatment with
PMA and ionomycin. There was a significant 10- and 2.7-
fold increase in the number of IFN-g–producing CD81
and CD41 T cells, respectively, in LCMV-immune mice
versus naive mice challenged with VV (Fig. 4, A and B).
To further examine whether IFN-g was playing a role in
the protective effect against heterologous viruses, we ini-
tially treated LCMV-immune mice with anti-IFN-g anti-
bodies, as previously described (31). In brief, we gave 0.2 ml
of a 1/5 dilution of anti-IFN-g ascites intraperitoneally
daily, in combination with a similar intravenous dose on
day 0 and day 3 of VV infection. In the first experiment at
4 d after VV infection there was a 20-fold increase in the
VV fat pad titer in the anti-IFN-g–treated group (LCMV-
immune 1 VV, 2.77 6 0.23 PFU/ml vs. LCMV-immune 1
VV 1 anti-IFN-g, 4.07 6 0.45 PFU/ml; n 5 5; P 5 0.04,
Student’s t test). In the second experiment at day 6 after
VV infection there was a 13-fold increase in the anti-IFN-
g–treated group (LCMV-immune 1 VV, 4.23 6 0.61
PFU/ml vs. LCMV-immune 1 VV 1 anti–IFN-g, 5.31 6
0.22; n 5 5; P 5 0.006, Student’s t test).
Figure 2. Protective effect of adoptively transferred LCMV-immune
splenocytes mediating heterologous T cell–mediated immunity against
unrelated viruses. C57BL/6 mice were injected intravenously with naive
or LCMV-immune leukocytes and challenged with VV (A and B) or PV
(C and D). LCMV-immune leukocytes were depleted of CD81 (A and
C) or CD41 (B and D) T cells before cell transfer. Spleens and fat pads
were harvested, homogenized, and plaque-assayed for viruses at 3–4 d af-
ter infection. The solid bars represent mice receiving adoptively trans-
ferred naive cells; the cross-hatched bars represent mice who received
adoptively transferred LCMV-immune cells; and the diagonally striped
bars represent mice who received adoptively transferred LCMV-immune
cells in vitro depleted of either CD4 or CD8 T cells. Each experiment is
representative of three similar experiments. *Represents statistically signif-
icant difference between naive and immunized groups of mice (Student’s
t test, P , 0.05).
Figure 3. (I) Increased IFN-g levels in peritoneal lavage fluid of
LCMV immune mice versus naive mice 3 d after challenge with VV (8 3
105 PFU), unlike challenge with PV (II). An Endogen mouse IFN-g
ELISA assay was done as per manufacturer’s protocol.
Figure 4. Increased numbers of IFN-g–secreting (A) CD81 and (B)
CD41 T cells in the peritoneum of LCMV-immune mice challenged
with VV (Day 3). Peritoneal cells were harvested from age-matched naive
and LCMV-immune C57BL/6 mice challenged with purified VV at day 3
of infection or from LCMV-immune mice challenged with control puri-
fied cell supernatant (day 3). The total number of CD81 and CD41 cells
(cross-hatched bars) and total number of IFN-g secreting CD81 and CD41
cells (solid bars) was determined as described in Materials and Methods.
*Represents a statistically significant difference from the LCMV-
immune1VV group (P , 0.01).1711 Selin et al.
To further confirm this observation, we extended these
studies into IFN-g receptor knockout (IFN-gR KO) mice.
Since the IFN-gR KO mice were on the 129/SEV back-
ground instead of the C57BL/6 background, normal 129/
SEV mice were used as controls (Fig. 5). The 129/SEV and
129 IFN-gR KO mice developed equivalent high frequency
LCMV-specific memory pCTL, as shown by limiting dilu-
tion assays (Fig. 5, A and B). 129/SEV mice immune to
LCMV developed protective heterologous immunity to PV
and VV, similar to that in the C57BL/6 mice. However,
IFN-gR KO mice immune to LCMV did not resist VV
infection, confirming a role for IFN-g in the control of VV
by LCMV-induced memory T cells (Fig. 6, A and B). Sim-
ilar experiments demonstrated that IFN-g was not required
for the protective effect against PV (Fig. 6, C and D), sug-
gesting the possibility that other cytokines or even direct
cytotoxicity by the cross-reactive CTL may be effective. A
role for cytotoxicity could not be easily addressed in these
systems, as cytotoxicity-deficient perforin KO mice de-
velop persistent LCMV infections instead of memory T cell
responses (32).
Heterologous Immunity between Viruses Predisposes a Host to Im-
munopathogenesis. Substantial evidence has been provided that
T cells can not only be mediators of protective immunity,
but also of immunopathology (10, 33–37). Our studies de-
scribed below of heterologous immunity between viruses
indicate that a previous virus infection may predispose a
host to a much more severe disease upon infection with an
unrelated heterologous virus. In general accordance with
an earlier report (22), mice immunized with LCMV, un-
like naive mice, developed severe immunopathology con-
sisting of extensive acute fat necrosis (AFN) with a cellular
infiltrate in visceral fat pads 5–7 d after VV challenge (Fig.
7). In contrast, prior immunity to PV or MCMV, although
protective against VV challenge, did not result in AFN on
VV infection. The leukocyte infiltrate within the abdominal
fat pads contained 19% 6 7 (SEM; n 5 2) CD41 T cells and
23% 6 5 (SEM; n 5 2) CD81 T cells and mediated CTL
activity against both VV- (8 6 4 lytic units per 106 cells;
n 5 5) and LCMV- (9.4 6 6.9 lytic units per 106 cells; n 5
5) infected targets. The CTL activity segregated to the
CD81 T cell population on sorting (data not shown).
Therefore, these fat pads contained infiltrates of activated
CTL specific not only for VV but also for LCMV. A reac-
tivation of the LCMV-specific memory splenic CTL by
VV has previously been documented (11, 12). Adoptive
transfer studies showed that splenocytes from LCMV-immune
mice not only provided some protective immunity against
VV synthesis, but also induced rather severe acute fatty ne-
crosis (Fig. 8 A). This immunopathology did not occur in
mice lacking IFN-g receptors (Fig. 8 B). Further, LCMV-
immune mice acutely infected with VV and treated with
anti-IFN-g daily had decreased evidence of AFN (level of
AFN: LCMV-immune 1 VV, 4 6 1.2; LCMV-immune
1 VV 1 anti-IFN-g, 1 6 0.5; n 5 5). As shown above,
LCMV-immune mice challenged with VV (Fig. 3 I) had
higher levels of IFN-g in the peritoneal fluid than did naive
mice challenged with VV. This enhanced IFN-g response
in immune mice may thus play a role in protective immu-
nity as well as in the induction of immunopathology. In
this sequence of viruses the immunological contribution of
the LCMV-specific memory cells may result in an over-
whelming delayed-type hypersensitivity-like cell-mediated
immune response, resulting in enhanced pathogenesis,
even though the VV is cleared more rapidly.
Figure 5. Normal CD81 T cell memory responses to LCMV in 129/
SEV (A) and IFN-gR KO (B) (reference 17) LCMV-immune mice as
determined by LDA. 129/SEV mice 1 and 2 were previously infected
with LCMV for 9 and 29 wk, respectively. IFN-gR KO mice 1 and 2
were previously infected with LCMV for 29 and 52 wk, respectively.
Figure 6. Role for IFN-g in T cell–mediated heterologous immunity
against VV but not PV after challenge of LCMV-immune mice. Naive
129/SEV mice or mice immunized (.6 wk) I.P. with LCMV (4 3 104
PFU) were challenged with VV (106 PFU; A and B) or PV (106 PFU; C
and D). In the same experiment, naive IFN-gR KO mice or mice which
were immunized with LCMV were challenged with VV (A and B) or PV
(C and D). The spleen (A and C) and fat pads (B and D) were harvested,
homogenized, and plaque-assayed for virus titers (22) at day 4 after the
second virus infection. (h, j) naive 129/SEV mice; (,,.) LCMV-
immune mice; (s, d) naive IFN-gR KO mice; (n, m) LCMV-immune
IFN-gR KO mice. The closed symbols demonstrate splenic virus titers
and the open symbols demonstrate fat pad virus titers. *Represents a sta-
tistically significant difference between naive and immunized groups of
mice (Student’s t test, P , 0.05). Each experiment is representative of
three (for VV) and two (for PV) experiments with similar results.1712 Protective Heterologous Antiviral Immunity
Discussion
Most models for the immune response to viral infections
have used infected animals sheltered from other environ-
mental pathogens, a rather unnatural circumstance. In this
study, we show that these sheltered mice responded quite
differently to infection than did mice previously exposed to
other pathogens, as early protective immunity can be me-
diated by memory T cells generated by a previous heterol-
ogous viral infection. Our results would suggest that both
memory CD41 and CD81 T cells can be reactivated, as
both populations were required for the protective immu-
nity to occur in the virus combinations tested. For instance,
in LCMV-immune versus a naive host challenged with
VV, both memory cell types were recruited early in infec-
tion into the peritoneal cavity, the site of virus challenge,
and were producing significantly more IFN-g, a cytokine
to which VV is very sensitive (17, 30). We have not exam-
ined the role of memory B cells in this system but clearly
memory T cells are required for this type of protective im-
munity.
Although T cells are generally thought to be highly spe-
cific for peptide–MHC complexes, more extensive investi-
gations have shown that a single T cell clone can recognize
two unrelated peptide sequences on the same protein, two
different proteins of the same virus, and two different pro-
teins from two unrelated viruses (38–40). It is not surpris-
ing that peptides from a second viral infection could cross-
react with and stimulate some of the many clones of T cells
comprising the memory pool specific for another virus. We
have reported that memory CD81 T cells can often cross-
react between heterologous viruses (12), and such cross-
reactive T cells may contribute to this more rapid early resis-
tance to a second infection. The T cell repertoire to each
new infection would be altered as cross-reactive memory
cells join in the response, resembling in some ways the
original antigenic sin network of antibody responses to dif-
ferent strains of influenza virus, where primary immunity is
boosted not by a homologous but, by a cross-reacting vac-
Figure 7. Acute fatty necrosis (AFN) in an LCMV-immune mouse challenged with VV. Absence of AFN in (I) nonchallenged LCMV-immune mice
and in (II) naive mice challenged with VV (day 5); (III) severe AFN in LCMV-immune mice challenged with VV (day 5).
Figure 8. (A, I) Increased level of AFN in mice on day 4 after adoptive
transfer of LCMV-immune splenocytes and challenge with VV. (II) De-
creased VV titer in fat pads of these same mice as described above. (B, I)
AFN was not present in LCMV-immune IFN-gR KO mice when chal-
lenged with VV (day 3). (II) No protective effect on fat pad VV titer in
these same mice. *Represents a statistically significant difference between
naive and immunized groups of mice (Student’s t test, P , 0.05). Each
experiment is representative of three experiments with similar results.1713 Selin et al.
cine of a different influenza virus serotype, and some of the
newly formed antibodies react better with the primary vi-
rus than with the virus actually eliciting the response (41).
Memory T cells are known to express high levels of adhe-
sion molecules (8–10) and to be easier to stimulate (13–16)
than naive cells, making them susceptible to low affinity
cross-reactive TcR triggering. Some reports have suggested
that memory T cells can be stimulated nonspecifically by
cytokines (5, 6, 42), and may be cross-activated by an in-
fection that does not require stimulation through their T
cell receptor by cross-reactive viral peptides. However,
data from our laboratory suggests that memory T cells do
not nonspecifically proliferate in response to an antigen to
which there are no cross-reactive TcR epitopes detectable
(43), and our experiments on heterologous immunity be-
tween viruses argue on behalf of cross-reactive memory
cells rather than nonspecific activation effects, because the
specific sequence of virus infections determines if there is
any protective immunity. Nevertheless, it is possible there
is some as yet unknown selective mechanism for cross-acti-
vation of different memory T cell populations. The contri-
bution of memory cells specific for one virus to the natural
resistance against another virus is presently not predictable
and is not necessarily reciprocal. If the immunodominant
memory T cell response to an earlier virus could recognize
a cross-reactive determinant on the challenge virus, the
challenge virus would find a large pool of memory T cells
capable of a rapid response. Should the challenge virus not
be recognized by part of the immunodominant memory T
cell repertoire, then less of a protective effect may ensue.
Individuals vary considerably in their responses to viral
infections, ranging from subclinical to severe. There are
many factors that contribute to this variation in responsive-
ness, including the dose and route of infection, as well as
the physiological state and genetic background of the host.
In this study, we show that memory T cells specific to un-
related viruses may also contribute to the host’s primary re-
sponse to a second virus. The beneficial effect of these early
protective memory T cells is to slow down the spread of
infection, much like a natural immune-mediated response,
allowing time for more suitable high affinity antigen-spe-
cific T and B cell responses to develop. It is reasonable to
expect that this level of resistance may be the difference be-
tween clinical and subclinical infections or lethal and non-
lethal infections. The detrimental immunopathological ef-
fect of memory T cells leads us to question whether they
may play a role in human infections like with Epstein-Barr
virus or varicella-zoster virus that lead to much more severe
disease in young adults than in young children, who pre-
sumably have a more restricted memory T cell repertoire
(44, 45). Reactivation of memory T cells may also play a
role in exacerbation of autoimmune diseases, such as multi-
ple sclerosis or diabetes. For example, in an experimental
model for chronic virus-induced CNS autoimmunity, dis-
ease may be induced by infection with a virus sharing
epitopes with a protein expressed in oligodendrocytes, and
this T cell–dependent disease could be exacerbated by a
second infection with an unrelated virus (46). Thus, alter-
ations in acute responses caused by the memory T cell
modulations induced by the host’s history of prior infec-
tions may have the paradoxical effect of producing both
beneficial protective heterologous immunity and/or im-
munopathology.
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